NPPA and cardiac hypertrophy: Moreover, the immunofluorescence staining of WGA (Fig. 4G, H) and the mRNA expression of hypertrophy markers (included atrial natriuretic peptide/ANP, brain natriuretic peptide/BNP, myosin heavy chain 7/MYH7) (Fig. 4I) together proved that HucMSCs administration attenuated cardiac hypertrophy on day 28 after MI.